Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using the same

• US 7,579,173 B2
• Filed: 01/09/2007
• Issued: 08/25/2009
• Est. Priority Date: 04/02/1998
• Status: Expired due to Fees

• Current Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Original Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Inventors: DeAngelis, Paul L., Jing, Wei
• Primary Examiner(s): Nashed; Nashaat T
• Assistant Examiner(s): MEAH, MOHAMMAD Y
• Application Number:
  US11/651,379
• Publication Number:
  US 20070128703A1
• Time in Patent Office: 959 Days
• Field of Search: None
• US Class Current: 435/97
• CPC Class Codes: A61K 39/102 Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61L 24/08 Polysaccharides A61L24/043 takes precedence
• CPC Class Codes: A61L 27/20 Polysaccharides
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: C07H 3/06 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: C07K 14/285 from Pasteurellaceae (F), e.g. Haemophilus influenza
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C08B 37/0063 Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
• CPC Class Codes: C08B 37/0069 Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
• CPC Class Codes: C08B 37/0072 Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
• CPC Class Codes: C08B 37/0075 Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: C12N 9/1048 Glycosyltransferases (2.4)
• CPC Class Codes: C12N 9/1051 Hexosyltransferases (2.4.1)
• CPC Class Codes: C12P 19/04 Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• CPC Class Codes: C12P 19/26 Preparation of nitrogen-containing carbohydrates
• CPC Class Codes: C12P 19/28 : N-glycosides
• CPC Class Codes: C12Q 1/689 : for bacteria

Abstract

The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate or chondroitin or heparin/heparosan synthases from Pasteurella, in order to create a variety of glycosaminoglycan oligosaccharides having a natural or chimeric or hybrid sugar structure with a targeted size that are substantially monodisperse in size.

Claims

1. A method for enzymatically producing defined glycosaminoglycan polymers comprising the steps of:

providing at least one functional acceptor, wherein the functional acceptor has at least two sugar units selected from the group consisting of uronic acid and hexosamine;

providing at least one recombinant glycosaminoglycan transferase having an empty acceptor site and being capable of elongating the at least one functional acceptor in a controlled and/or repetitive fashion to form extended glycosaminoglycan molecules, and wherein the at least one recombinant glycosaminoglycan transferase is selected from the group consisting of;

(a) a recombinant glycosaminoglycan transferase having the amino acid sequence as set forth in SEQ ID NO;

4;

(b) a recombinant glycosaminoglycan transferase encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs;

3 and 26;

(c) a recombinant glycosaminoglycan transferase having an amino acid sequence encoded by a nucleotide sequence capable of hybridizing to the complement of at least one of SEQ ID NOS;

3 and 26 under hybridization conditions comprising hybridization at a temperature of 68°

C. in 5x SSC/5x Denhardt'"'"'s solution/1.0% SDS, followed with washing in 3x SSC at 42°

;

(d) a chimeric recombinant glycosaminoglycan transferase having an amino acid sequence selected from the group consisting of SEQ ID NOs;

74-76 and 85;

(e) a recombinant glycosaminoglycan transferase having an amino acid sequence that is at least 90% identical to SEQ ID NO;

4; and

(f) a recombinant glycosaminoglycan transferase encoded by a nucleotide sequence that is at least 90% identical to at least one of SEQ ID NOS;

3 and 26; and

providing at least one UDP-sugar selected from the group consisting of UDP-GIcUA, UDP-GIcNAc, UDP-GIc, UDP-GaINAc, UDP-GIcN and UDP-GaIN in a stoichiometric ratio to the at least one functional acceptor such that the at least one recombinant glycosaminoglycan transferase elongates the at least one functional acceptor to provide glycosaminoglycan polymers wherein the glycosaminoglycan polymers have a desired size distribution such that the glycosaminoglycan polymers are substantially monodisperse in size such that the glycosaminoglycan polymers have a polydispersity value in a range of from 1 .0 to 1.5, and wherein the desired size distribution is obtained by controlling the stoichiometric ratio of UDP-sugar to functional acceptor.

2. The method of claim 1 wherein, in the step of providing at least one functional acceptor, uronic acid is further defined as a uronic acid selected from the group consisting of GIcUA, iduronic acid (IdoUA), and GaIUA, and wherein hexosamine is further defined as a hexosamine selected from the group consisting of GIcNAc, GaINAc, GIcN, and GaIN.

3. The method of claim 1 wherein, in the step of providing at least one functional acceptor, the functional acceptor is at least one of:

(a) an HA oligosaccharide having between three sugar units and a molecular weight of about 4.2 kDa;

(b) an HA polymer having a mass in a range of from about 3.5 kDa to about 2 MDa;

(c) a chondroitin oligosaccharide comprising at least three sugar units;

(d) a chondroitin polymer;

(e) a chondroitin sulfate polymer;

(f) a heparin polymer;

(g) a heparan polymer;

(h) a heparosan polymer; and

(i) an extended acceptor selected from the group consisting of HA chains, chondroitin chains, heparosan chains, mixed glycosaminoglycan chains, analog containing chains, and combinations thereof.

4. The method of claim 1 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase is a recombinant chondroitin synthase.

5. The method of claim 1 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase comprises a recombinant single action glycosyltransferase capable of adding only one of GIcUA, GIcNAc, GIc, GaINAc, GIcN, and GaIN.

6. The method of claim 1 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase comprises a recombinant synthetic chimeric glycosaminoglycan transferase capable of adding two or more of GIcUA, GIcNAc, GIc, GaINAc, GIcN, and GaIN.

7. The method of ,claim 1, further comprising the step of providing a divalent metal ion, wherein the divalent metal ion is selected from the group consisting of manganese, magnesium, cobalt, nickel and combinations thereof.

8. The method of claim 1, wherein the method occurs in a buffer having a pH from about 6 to about 8.

9. The method of claim 1 wherein the substantially monodisperse glycosaminoglycan polymers have a molecular weight in a range of from about 3.5 kDa to about 0.5 MDa, and have a polydispersity value in a range of from about 1.0 to about 1.1.

10. The method of claim 1 wherein the substantially monodisperse glycosaminoglycan polymers have a molecular weight in a range of from about 0.5 MDa to about 4.5 MDa, and have a polydispersity value in a range of from about 1.0 to about 1.5.

11. The method of claim 10 wherein the substantially monodisperse glycosaminoglycan polymers have a polydispersity value in a range of from about 1.0 to about 1.2.

12. The method of claim 1 wherein, in the step of providing at least one functional acceptor, the at least one functional acceptor further comprises a moiety selected from the group consisting of a fluorescent tag, a radioactive tag, an affinity tag, a detection probe, a medicant, and combinations thereof.

13. The method of claim 1 wherein, in the step of providing at least one UDP-sugar, at least one UDP-sugar is radioactively labeled.

14. The method of claim 1 wherein the glycosaminoglycan polymers are chimeric or hybrid glycosaminoglycan polymers.

15. The method of claim 1 wherein, in the step of providing at least one functional acceptor, the at least one functional acceptor is sulfated or is a modified oligosaccharide.

28. The method of claim 1, wherein the defined glycosaminoglycan polymers are capable of acting as a bioadhesive sealant, a tissue engineering aid, a cell matrix mimetic, a cell behavior or growth modulator, a drug delivery agent, or combinations thereof.

16. A method for enzymatically producing defined glycosaminoglycan polymers comprising the steps of:

providing at least one functional acceptor, wherein the functional acceptor is selected from the group consisting of an HA polymer, a chondroitin polymer, a chondroitin sulfate polymer, a heparosan polymer, mixed GAG chains, analog containing chains and combinations thereof;

providing at least one recombinant glycosaminoglycan transferase having an empty acceptor site and being capable of elongating the at least one functional acceptor in a controlled and/or repetitive fashion to form extended glycosaminoglycan molecules, and wherein the at least one recombinant glycosaminoglycan transferase is selected from the group consisting of;

(a) a recombinant glycosaminoglycan transferase having the amino acid sequence as set forth in SEQ ID NO;

4;

(b) a recombinant glycosaminoglycan transferase encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs;

3 and 26;

(c) a recombinant glycosaminoglycan transferase having an amino acid sequence encoded by a nucleotide sequence capable of hybridizing to the complement of at least one of SEQ ID NOs;

3 and 26 under hybridization conditions comprising hybridization at a temperature of 68°

C. in 5x SSC/5x Denhardt'"'"'s solution/1.0% SDS, followed with washing in 3x SSC at 42°

C.;

(d) a chimeric recombinant glycosaminoglycan transferase having an amino acid sequence selected from the group consisting of SEQ ID NOs;

74-76 and 85;

(e) a recombinant glycosaminoglycan transferase having an amino acid sequence that is at least 90% identical to SEQ ID NO;

4; and

(f) a recombinant glycosaminoglycan transferase encoded by a nucleotide sequence that is at least 90% identical to at least one of SEQ ID NOS;

3 and 26; and

providing at least one UDP-sugar selected from the group consisting of UDP-GIcUA, UDP-GIcNAc, UDP-GIc, UDP-GaINAc, UDP-GIcN, and UDP-GaIN in a stoichiometric ratio to the at least one functional acceptor such that the at least one recombinant glycosaminoglycan transferase elongates the at least one functional acceptor to provide glycosaminoglycan polymers wherein the glycosaminoglycan polymers have a desired size distribution greater than 1 MDa, and wherein the desired size distribution is obtained by controlling the stoichiometric ratio of UDP-sugar to functional acceptor.

17. The method of claim 16 wherein, in the step of providing at least one functional acceptor, the functional acceptor is an HA polymer having a mass in a range of from about 3.5 kDa to about 2 MDa.

18. The method of claim 16 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase is a recombinant chondroitin synthase.

19. The method of claim 16 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase comprises a recombinant single action glycosyltransferase capable of adding only one of GIcUA, GIcNAc, GIc, GaINAc, GIcN and GaIN.

20. The method of claim 16 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase comprises a recombinant synthetic chimeric glycosaminoglycan transferase capable of adding two or more of GIcUA, GIcNAc, GIc, GaINAc, GIcN, and GaIN.

21. The method of claim 16, further comprising the step of providing a divalent metal ion selected from the group consisting of manganese, magnesium, cobalt, nickel and combinations thereof.

22. The method of claim 16, wherein the method occurs in a buffer having a pH from about 6 to about 8.

23. The method of claim 16 wherein, in the step of providing at least one functional acceptor, the at least one functional acceptor further comprises a moiety selected from the group consisting of a fluorescent tag, a radioactive tag, an affinity tag, a detection probe, a medicant, and combinations thereof.

24. The method of claim 16 wherein, in the step of providing at least one UDP-sugar, at least one UDP-sugar is radioactively labeled.

25. The method of claim 16 wherein the glycosaminoglycan polymers are chimeric or hybrid glycosaminoglycans.

26. The method of claim 16 wherein, in the step of providing at least one functional acceptor, the at least one functional acceptor is sulfated or is a modified oligosaccharide.

27. A method for producing a polysaccharide biomaterial containing a medicament delivery assembly, comprising the steps of:

providing at least one functional acceptor, wherein the functional acceptor has at least two sugar units selected from the group consisting of uronic acid and hexosamine;

providing at least one recombinant glycosaminoglycan transferase having an empty acceptor site and being capable of elongating the at least one functional acceptor in a controlled and/or repetitive fashion to form extended glycosaminoglycan molecules, and

wherein the at least one recombinant glycosaminoglycan transferase is selected from the group consisting of;

(a) recombinant glycosaminoglycan transferase having the amino acid sequence as set forth in SEQ ID NO;

4;

(b) a recombinant glycosaminoglycan transferase encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs;

3 and 26;

(c) a recombinant glycosaminoglycan transferase having an amino acid sequence encoded by a nucleotide sequence capable of hybridizing to the complement of at least one of SEQ ID NOs;

3 and 26 under hybridization conditions comprising hybridization at a temperature of 68°

C. in 5x SSC/5x Denhardt'"'"'s solution/1.0% SDS, followed with washing in 3x SSC at 42°

C.;

(d) a chimeric recombinant glycosaminoglycan transferase having an amino acid sequence selected from the group consisting of SEQ ID NOs;

74-76 and 85;

(e) a recombinant glycosaminoglycan transferase having an amino acid sequence that is at least 90% identical to SEQ ID NO;

4; and

(f) a recombinant glycosaminoglycan transferase encoded by a nucleotide sequence that is at least 90% identical to at least one of SEQ ID NOS;

3 and 26; and

providing at least one UDP-sugar selected from the group consisting of UDP-GIcUA, UDP-GIcNAc, UDP-GIc, UDP-GaINAc, UDP-GIcN, and UDP-GaIN in a stoichiometric ratio to the at least one functional acceptor such that the at least one recombinant glycosaminoglycan transferase elongates the at least one functional acceptor to provide glycosaminoglycan polymers wherein the glycosaminoglycan polymers have a desired size distribution such that the glycosaminoglycan polymers are substantially monodisperse in size such that the glycosaminoglycan polymers have a polydispersity value in a range of from 1.0 to 1.5, and wherein the desired size distribution is obtained by controlling the stoichiometric ratio of UDP-sugar to functional acceptor, and whereby the glycosaminoglycan polymers are capable of acting as a polysaccharide bioadhesive;

providing at least one medicament delivery assembly containing one or more medicaments entrapped therein and deliverable within a wound site or a surgical site; and

mixing the prepared polysaccharide bioadhesive with the at least one medicament delivery assembly, wherein the prepared polysaccharide bioadhesive entraps the at least one medicament delivery assembly to produce a polysaccharide biomaterial containing a medicament delivery system.